Projet Phd (Horizon 2020, appel à projets 2015)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : CLOSED

The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of human cancers. Therefore, PI3Ks have emerged as important targets for drug discovery and, during 2014, the first PI3K inhibitor was approved by FDA in the US for the treatment of a lymphocytic leukaemia. Nonetheless, our understanding of PI3K-mediated signalling is still poor and only a fraction of the potential therapeutic applications have been addressed so far, leaving a large amount of translational work unexplored. Europe features a set of top quality research institutions and pharmaceutical companies focused on PI3K studies but their activities have been so far scattered. This proposal fills this gap by providing a multidisciplinary network (biochemistry, mouse studies, disease models, drug development, software development) and an unprecedented training opportunity from the bench to the bedside (from pre-clinical discoveries to clinical trials), through cutting edge molecular biology, drug discovery and clinical trial organization. The proposal is aimed at training young investigators in deep understanding of the different PI3K isoforms in distinct tissues and to translate this knowledge into a new generation of PI3K inhibitors, treatment modalities and into identify new uses for existing PI3K inhibitors.

Mots clés : pi3k isoforms, kinase dead mice, oncology, lipid and protein biochemistry, cell signalling, angiogenesis, immunity, endosomal trafficking, drug development, skeletal muscle disease

Participants :
- CERCA Institution (Espagne) — Partner, beneficiary, Recherche, subvention : 247872.96 €
- Arivis ag (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 214603.08 €
- University of Basel (Suisse) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 265226.76 €
- Centre européen de recherche en biologie et en médecine (France) — Partner, beneficiary, Recherche, subvention : 262875.6 €
- UK Research and Innovation (Royaume-Uni) — Partner, beneficiary, Recherche, subvention : 440297.14 €
- University of Turin (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 258061.32 €
- Forschungsverbund Berlin (Allemagne) — Partner, beneficiary, Recherche, subvention : 498432.96 €
- Centre européen de recherche en biologie et en médecine (France) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 106278.62 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 546575.76 €
- Ubik media s.l. (Espagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Institut d'Investigació Biomédica de Bellvitge (Espagne) — Coordinator, beneficiary, Recherche, subvention : 530172.72 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 525751.2 €